Health2Sync

About Health2Sync

Health2Sync, founded in 2013 by Ed Deng, Ken Lai, and Erin Chung, provides a digital health management platform focused on chronic diseases, primarily diabetes. The impetus for the company's creation was personal; both Deng and Lai came from families with healthcare professionals and had witnessed relatives struggle with diabetes management. Deng, a serial entrepreneur with a background in investment banking at Lehman Brothers and marketing at a mobile tech firm, saw an opportunity to apply data-driven technological solutions to behavior management in chronic care.

The company operates in the digital health and chronic disease management market, serving patients directly, as well as partnering with healthcare providers, pharmaceutical companies, and insurers. Its business model involves providing a free mobile application with a premium subscription option for advanced features, alongside enterprise solutions for clinics, hospitals, and corporate partners. Revenue is generated through these premium subscriptions and collaborations with stakeholders like Sanofi, Novo Nordisk, Abbott, and various insurers to provide integrated care solutions. As of March 2025, Health2Sync has raised a total of $30.5 million over four funding rounds, with its latest Series C round securing $20 million led by Taiwania Capital. This funding is aimed at fueling expansion in Japan, South Korea, and Australia, developing new programs for weight management and hypertension, and preparing for an IPO in Taiwan.

The core product is the Health2Sync mobile app, which allows users to log blood glucose, blood pressure, weight, diet, and medication data. The platform functions as an IoT-based system, syncing with over 80 devices including glucose meters, CGMs like Abbott's FreeStyle Libre, smart insulin pens from companies like Sanofi and Novo Nordisk, and fitness trackers. The app provides data visualization, reminders, and personalized feedback to help users manage their condition. A key feature is the ability for users to share their data with family, friends, and healthcare professionals, who can monitor progress and communicate through a dedicated patient management platform. The company has also developed "Insultrate," a digital therapeutic software for insulin dosage titration, co-developed with Sanofi and approved in Taiwan. With a global user base of over 1.48 million, the platform has established itself as a significant player in Asia's chronic disease management space.